PDCD1 and hematopoietic and lymphoid cell neoplasm: Due to its frequent co-expression with PD-1, TIM-3 has been implicated as a potential mechanism of resistance to PD-1-targeted therapies and is currently under investigation as a therapeutic target across multiple malignancies, including hematologic cancers [94,95].